Docent lecture: Targeted Metabolomics in Clinical Samples

  • Date: –14:30
  • Location: Biomedicinskt centrum, BMC Scheelerummet C6:3 BMC, Husargatan 3
  • Lecturer: PhD, researcher Kumari Ubhayasekera
  • Website
  • Organiser: Institutionen för kemi-BMC
  • Contact person: Jonas Bergquist
  • Phone: 070-9621393
  • Docentföreläsning

The lecture is an obligatory teaching test for those applying for admittance as docent (associate professor) and it should be possible for students and others with basic academic education in the relevant field to follow it. The lecture will last for 45 minutes and afterwards the audience may ask questions. The lecture will be given in English.


Metabolomics is the systematic identification and quantitation of biologically relevant small molecules in a given biological sample (cell, tissue, or organism). It represents the functional end-point of physiological and pathophysiological processes representing both genetic predisposition and environmental influences. Metabolomics aims to measure a wide range of small molecules in the context of physiological stimuli or disease states. The methodologies for these measurements fall into two distinct groups: untargeted metabolomics, an intended comprehensive analysis of all the measurable analytes in a sample including chemical unknowns, and targeted metabolomics, the measurement of defined groups of chemically characterized and biochemically annotated metabolites. The focus of this lecture is to discuss the methodologies used for targeted metabolomics experiments, and the advantages of this approach. A summary of the procedures for extracting the targeted metabolites (free fatty acids, amino acids, steroids, and oxycholesterols), intermediary pathway metabolites (from tryptophan metabolism, TCA and methionine cycles) will be described. The analytical protocols based on supercritical chromatography and liquid chromatography hyphenated with tandem mass spectrometry will be outlined with several examples of valuable findings from metabolomics-led studies on diabetes, neurodegenerative disorders, and cancer.  The metabolomics research offers ways toward personalized medicine, placing the targeted metabolomics as a platform technology for clinical chemistry.